Characterizing Breast Cancer With 18F-FES PET/CT

Chinese Academy of Medical Sciences & Peking Union Medical College

Status: Enrolling

Conditions: Breast Cancer

Treatments: Diagnostic Test: 18F-FES PET/CT scan

Study type: Interventional

Funder types: Other

Identifiers

NCT05613270

PekingUMCH-FES-BC-1

Details and patient eligibility

About

18F-fluoroestradiol (FES) is radioactive labeled estradiol, developed for in vivo visualization of estrogen receptor (ER) using positron emission tomography (PET). In this prospective study, 18F-FES PET/CT will be used to evaluate ER activity of metastatic disease and their potential sensitivity to endocrine therapy in ER-positive breast cancer.

Enrollment: 50 estimated patients

Sex: Female

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• suspected or confirmed metastatic ER-positive breast cancer;
• 18F-FDG PET/CT within two weeks;
• signed written consent.

Exclusion criteria

• pregnancy;
• breastfeeding;
• any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

18F-FES PET/CT

Experimental group

Description:

Inject 18F-FES and then perform PET/CT scan.

Treatment:

Diagnostic Test: 18F-FES PET/CT scan